Pan-cancer analysis of ACHE as a biomarker forcancer prognosis and immunotherapy

Authors

  • Tianling Liao Department of Traditional Chinese Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China Author https://orcid.org/0009-0006-7608-8290
  • Qingming Huang Department of Urology, Cancer Hospital of Guangxi Medical University, Nanning, Guangxi, China Author
  • Han Tang Department of Urology, Cancer Hospital of Guangxi Medical University, Nanning, Guangxi, China Author
  • Huadong Xie Department of Urology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China Author
  • Kangji Liao Department of Urology, Wuming Hospital of Guangxi Medical University, Nanning, Guangxi, China Author
  • Zhengwei Su Department of Urology, Cancer Hospital of Guangxi Medical University, Nanning, Guangxi, China Author
  • Chengjie Ban Department of Urology, Cancer Hospital of Guangxi Medical University, Nanning, Guangxi, China Author
  • Zhi Cheng Department of Urology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China Author
  • Xianlin Yi yixianlin@gxmu.edu.cn Author

DOI:

https://doi.org/10.4238/z2qb9g57

Keywords:

ACHE, Pan-cancer, Prognosis, Immune Infiltration, Bioinformatics

Abstract

Background: ACHE belongs to the carboxylesterase family and is also classified as the acylhydrolase superfamily.It plays an important role in many cancers. Methods: Using TCGA multi-omics data, we employed R software and various online tools to analyze the differential expression of ACHE in 33 tumor tissues versus normal tissues, survival prognosis, immune infiltration, and potential biological functions. Results: ACHE affects the prognosis of multiple cancers and is closely associated with the tumor immune microenvironment and tumor immune cell infiltration. Thus, ACHE may serve as a prognostic biomarker for cancer. Conclusion: Comprehensive pancancer analysis identifies ACHE as correlated with immune infiltration and cancer prognosis in various tumors, suggesting its potential as a novel immune modulation target, and providing new insights for cancer treatment.

Author Biographies

  • Tianling Liao, Department of Traditional Chinese Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

    Department of Urology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, China.

    Department of Traditional Chinese Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.

  • Qingming Huang, Department of Urology, Cancer Hospital of Guangxi Medical University, Nanning, Guangxi, China

    Department of Urology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, China.

    Department of Urology, Wuming Hospital of Guangxi Medical University, Nanning, Guangxi, China.

    Department of Urology, Cancer Hospital of Guangxi Medical University, Nanning, Guangxi, China.

  • Han Tang, Department of Urology, Cancer Hospital of Guangxi Medical University, Nanning, Guangxi, China

    Department of Urology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, China.

    Department of Urology, Wuming Hospital of Guangxi Medical University, Nanning, Guangxi, China.

    Department of Urology, Cancer Hospital of Guangxi Medical University, Nanning, Guangxi, China.

  • Huadong Xie, Department of Urology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

    Department of Urology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, China.

    Department of Urology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.

  • Kangji Liao, Department of Urology, Wuming Hospital of Guangxi Medical University, Nanning, Guangxi, China

    Department of Urology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, China.

    Department of Urology, Wuming Hospital of Guangxi Medical University, Nanning, Guangxi, China.

  • Zhengwei Su, Department of Urology, Cancer Hospital of Guangxi Medical University, Nanning, Guangxi, China

    Department of Urology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, China.

    Department of Urology, Wuming Hospital of Guangxi Medical University, Nanning, Guangxi, China.

    Department of Urology, Cancer Hospital of Guangxi Medical University, Nanning, Guangxi, China.

  • Xianlin Yi, yixianlin@gxmu.edu.cn

    Department of Traditional Chinese Medicine, The First Affiliated Hospital of
    Guangxi Medical University, Nanning, Guangxi, China

    Department of Urology, Maternal and Child Health Hospital of Hubei Province,
    Tongji Medical College, Huazhong University of Science and Technology, China.

    Department of Urology, Wuming Hospital of Guangxi Medical University, Nanning,
    Guangxi, China

cancer

Downloads

Published

2025-06-14

Issue

Vol. 24 No. 1 (2025)

Section

Articles

How to Cite

Pan-cancer analysis of ACHE as a biomarker forcancer prognosis and immunotherapy. (2025). Genetics and Molecular Research, 24(1), 1-17. https://doi.org/10.4238/z2qb9g57

Similar Articles

You may also start an advanced similarity search for this article.